Microalbuminuria, chronic renal disease, and the effects of the metabolic syndrome on cardiovascular events.
In March 2007, a panel discussion was held following a hypertension symposium in New York, New York. The panel was moderated by Marvin Moser, MD, Clinical Professor of Medicine at the Yale University School of Medicine, New Haven, Connecticut. Serving on the panel were James R. Sowers, MD, Professor of Medicine and Physiology at the University of Missouri, Columbia, Missouri, and Henry R. Black, MD, Clinical Professor of Medicine at the New York University School of Medicine, New York, New York. This expert panel discussion was supported by Novartis and each author received an honorarium from Novartis for time and effort spent participating in the discussion and reviewing the transcript for important intellectual content prior to publication. The authors maintained full control of the discussion and the resulting content of this article; Novartis had no input in the choice of topic, speakers, or content.
Moser
Marvin
M
Sowers
James R
JR
Black
Henry R
HR
D000419:Albuminuria / Q000150:complications*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D006973:Hypertension / Q000150:complications; D007676:Kidney Failure, Chronic / Q000150:complications*; D024821:Metabolic Syndrome / Q000150:complications*; D009203:Myocardial Infarction / Q000209:etiology*; D012307:Risk Factors; D013223:Statistics as Topic; D020521:Stroke / Q000209:etiology*